Less-frequent cystoscopy surveillance

Regular follow-ups and standard care

Non-invasive genomic urine test that can reliably detect, monitor, and predict the risk of urothelial cancer or its recurrence, potentially before signs and symptoms develop or become detectable by historical standards of care.

The rate of cystoscopies (cystoscopies per month), compared between the De-intensified and the standard surveillance arms, is the primary outcome measure.

An event is defined as: high-grade recurrence, progression to muscle invasive disease, or metastatic disease

We will compare the rate of any recurrences (including low-grade) between the De-intensified and the standard surveillance groups

After 50% enrollment, the rate of conversion from low-risk on the utDNA test to high risk will be evaluated at 3 months. If this rate exceeds 50%, the study will be terminated for futility.